0001214659-24-013689.txt : 20240802 0001214659-24-013689.hdr.sgml : 20240802 20240802171601 ACCESSION NUMBER: 0001214659-24-013689 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240701 FILED AS OF DATE: 20240802 DATE AS OF CHANGE: 20240802 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KAZIMI A J CENTRAL INDEX KEY: 0001075050 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33637 FILM NUMBER: 241172193 MAIL ADDRESS: STREET 1: 1207 17TH AVENUE SUITE 103 CITY: NASHVILLE STATE: TN ZIP: 37212 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CUMBERLAND PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001087294 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2525 WEST END AVENUE STREET 2: SUITE 950 CITY: NASHVILLE, STATE: TN ZIP: 37203 BUSINESS PHONE: 615-255-0068 MAIL ADDRESS: STREET 1: 2525 WEST END AVENUE STREET 2: SUITE 950 CITY: NASHVILLE STATE: TN ZIP: 37203 4 1 marketforms-66719.xml PRIMARY DOCUMENT X0508 4 2024-07-01 0001087294 CUMBERLAND PHARMACEUTICALS INC CPIX 0001075050 KAZIMI A J 1600 WEST END AVE. SUITE 1300 NASHVILLE TN 37203 true true true false Chairman and CEO 1 Common Stock 2024-07-01 5 L false E 44 1.47 A 5696055 D Common Stock 2024-07-02 5 L false E 44 1.48 A 5696099 D Common Stock 2024-07-03 5 L false E 54 1.52 A 5696153 D Common Stock 2024-07-05 5 L false E 44 1.50 A 5696197 D Common Stock 2024-07-08 5 L false E 44 1.49 A 5696241 D Common Stock 2024-07-09 5 L false E 44 1.50 A 5696285 D Common Stock 2024-07-10 5 L false E 44 1.50 A 5696329 D Common Stock 2024-07-11 5 L false E 44 1.47 A 5696373 D Common Stock 2024-07-12 5 L false E 27 1.49 A 5696400 D Common Stock 2024-07-15 5 L false E 44 1.48 A 5696444 D Common Stock 2024-07-16 5 L false E 40 1.50 A 5696484 D Common Stock 2024-07-17 5 L false E 14 1.45 A 5696498 D Common Stock 2024-07-18 5 L false E 44 1.48 A 5696542 D Common Stock 2024-07-19 5 L false E 27 1.48 A 5696569 D Common Stock 2024-07-22 5 L false E 44 1.49 A 5696613 D Common Stock 2024-07-23 5 L false E 44 1.50 A 5696657 D Common Stock 2024-07-24 5 L false E 44 1.50 A 5696701 D Common Stock 2024-07-25 5 L false E 34 1.49 A 5696735 D Common Stock 2024-07-26 5 L false E 44 1.50 A 5696779 D Common Stock 2024-07-29 5 L false E 44 1.49 A 5696823 D Common Stock 2024-07-30 5 L false E 14 1.48 A 5696837 D Common Stock 2024-07-31 5 L false E 44 1.45 A 5696881 D The reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2024. A.J. Kazimi by /s/ John Hamm as attorney-in-fact 2024-08-02